The tweet was deleted by the author.
But we saved everything 🙂.
Humacyte is gearing up for a significant presence at the VEITH Symposium 2025. The company will offer six presentations focusing on its Acellular Tissue Engineered Vessel, providing substantial educational opportunities on Wednesday and Thursday, November 19th and 20th.
The sessions will be part of Podium Session 5 on Concourse A, promising in-depth insights into Humacyte's pioneering technologies in tissue engineering. Innovators and attendees at the symposium are expected to gain valuable knowledge directly related to Humacyte's advanced research and developments in this field.
Humacyte continues to play a pivotal role in advancing medical technology by exploring new fronts in tissue engineering, making these presentations highly anticipated by attendees at the VEITH Symposium.
Humacyte’s forthcoming presentations build on a trajectory of innovation demonstrated in previous unveilings, notably its introduction of the bioengineered vessel, Symvess, at the Veith Symposium. Those advances, detailed in the original showcase of Symvess and its innovative capabilities, underscore the company’s sustained commitment to pushing the boundaries of tissue engineering and vascular technology.